Beverly Moy

16PUBLICATIONS
88CO-AUTHORS
Predictive and prognostic markersCancer geneticsCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsLiquid biopsies
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (16)

|Oct 22, 2026
Actionable genetic landscape and dynamics in circulating DNA from 12,827 patients with metastatic breast cancer.

|Jan 27, 2025
Impact of Race/Ethnicity on Clinical and Genomic Characteristics, Trial Participation, and Genotype-Matched Therapy among Patients with Metastatic Breast Cancer.

Rupali Sood, Andrzej Niemierko, Lianne Ryan

|Jan 08, 2025
Adjuvant endocrine therapy with cyclin-dependent kinase 4/6 inhibitor, ribociclib, for localized hormone receptor-positive/HER2- breast cancer (LEADER).

Laura M Spring, Lauren Scarpetti, Arielle J Medford

|Jan 02, 2025
TOP1 Mutations and Cross-Resistance to Antibody-Drug Conjugates in Patients with Metastatic Breast Cancer.

Rachel O Abelman, Bogang Wu, Haley Barnes

|Nov 12, 2024
Deficits of Molecular Prognosis/Diagnosis Studies in Underserved Populations.

Arielle J Medford, Beverly Moy

|May 06, 2024
Antibody-Drug Conjugate Sacituzumab Govitecan Enables a Sequential TOP1/PARP Inhibitor Therapy Strategy in Patients with Breast Cancer.

Aditya Bardia, Sheng Sun, Nayana Thimmiah

Pageof 3

Frequent Collaborators

7 joint publications

Aditya Bardia

7 joint publications

Steven J Isakoff

6 joint publications

Leif W Ellisen

6 joint publications

Laura Spring